Kiora Pharmaceuticals CDO to Resign April 17; Phase 2 100µg Cohort Initiated
Eric Daniels will resign as Chief Development Officer on April 17, 2026, prompting a search for his successor. The ABACUS-2 Phase 2 trial secured approval to enroll remaining 50µg patients and begin the 100µg cohort, and the KLARITY Phase 2 trial has cleared all safety checkpoints with enrollment ongoing.
1. Leadership Transition
Eric Daniels, M.D., MBA, will depart from his role as Chief Development Officer on April 17, 2026. The company has initiated an executive search to identify a successor capable of advancing its clinical development strategy.
2. ABACUS-2 Phase 2 Trial Update
Following a planned safety review, the ABACUS-2 Phase 2 clinical trial of KIO-301 received approval to enroll the remaining patients in the 50µg dose cohort and was cleared to initiate the 100µg dose cohort, maintaining momentum in its retinal disease program.
3. KLARITY Phase 2 Trial Update
In the KLARITY Phase 2 study of KIO-104 for macular edema, all scheduled safety checkpoints have been cleared and patient enrollment continues through Kiora’s established CRO network.